Exelixis, Inc. (EXEL) Posts Q1 EPS Loss of $0.24
Tweet
Share
E-mailGet Alerts EXEL Hot Sheet
Price: $50.38 --0%
Financial Fact:
Total operating expenses: 61.39M
Today's EPS Names:
VAXX, NMRD, EGRX, More
Financial Fact:
Total operating expenses: 61.39M
Today's EPS Names:
VAXX, NMRD, EGRX, More
Join SI Premium – FREE
Exelixis, Inc. (NASDAQ: EXEL) reported Q1 EPS of ($0.24), $0.04 worse than the analyst estimate of ($0.20). Revenue for the quarter came in at $35.9 million versus the consensus estimate of $37.39 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance
- Ascendis Pharma (ASND) Tops Q2 EPS by 132c
- Bending Spoons S.p.A. (BSP) Tops Q2 EPS by 19c; offers guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
